Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has appointed Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, the company announced today. The additions bring deep expertise in biotechnology, drug delivery, and central nervous system (CNS) clinical development, supporting Helus Pharma's pipeline of novel serotonergic agonists (NSAs) targeting major depressive disorder and generalized anxiety disorder.
Dr. Robert Langer, a renowned figure in drug delivery and biotechnology, is one of the most cited researchers in history, with over 1,500 publications and 1,400 issued or pending patents. His work has been instrumental in the development of controlled-release drug delivery systems and has been recognized with numerous awards, including the National Medal of Science and the Queen Elizabeth Prize for Engineering. Dr. Stephen Brannan brings extensive experience in CNS clinical development, having held senior roles at several pharmaceutical companies and contributing to the development of multiple approved medications for psychiatric disorders.
The appointments underscore Helus Pharma's commitment to disciplined, evidence-based drug development as it advances its lead programs. HLP003, a proprietary NSA, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
"We are thrilled to welcome Dr. Langer and Dr. Brannan to our Scientific Advisory Board," said a Helus Pharma spokesperson. "Their unparalleled expertise will be invaluable as we continue to develop innovative treatments for mental health conditions that address significant unmet needs."
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to improve the treatment landscape for depression, anxiety, and other mental health conditions through its proprietary NSAs.
For more information, visit the full press release at https://ibn.fm/CyjTq. Company updates are available at www.helus.com.
